<DOC>
	<DOCNO>NCT01611896</DOCNO>
	<brief_summary>The purpose study investigate selenium supplementation standard treatment anti-thyroid drug patient Graves ' hyperthyroidism , lead few people anti-thyroid treatment failure faster remission , term better quality life first year treatment patient stay remission .</brief_summary>
	<brief_title>Selenium Supplementation Versus Placebo Patients With Graves ' Hyperthyroidism</brief_title>
	<detailed_description />
	<mesh_term>Hyperthyroidism</mesh_term>
	<mesh_term>Graves Disease</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>Age 18 year old . Active Graves ' hyperthyroidism ( suppress TSH ( &lt; 0.1 ) positive TRAb ) measure within last two month prior inclusion date . Written inform consent Major comorbidity , make participant unlikely continuously receive trial intervention intervention period . Previous treatment radioactive iodine . Current ATD treatment receive two month . Treatment immunomodulatory drug , cyclosporine A , methotrexate , cyclophosphamide . Allergy towards component selenium placebo pill . Pregnant breastfeed woman . Intake selenium supplementation 70 µg per day ( 70 µg corresponds amount multivitamin tablet ) . Unable read understand Danish . Lack inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Graves ' hyperthyroidism</keyword>
	<keyword>Graves ' disease</keyword>
	<keyword>Selenium</keyword>
	<keyword>Quality Life</keyword>
	<keyword>ThyPRO</keyword>
	<keyword>Autoimmunity</keyword>
</DOC>